Determination of intact oxaliplatin in human plasma using high performance liquid chromatography-tandem mass spectrometry

J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Dec 15;876(2):277-82. doi: 10.1016/j.jchromb.2008.10.055. Epub 2008 Nov 7.

Abstract

A HPLC-tandem mass spectrometry method was developed and validated for the quantitation of intact oxaliplatin in human plasma. Plasma ultrafiltrates were precipitated with acetonitrile and separation was performed on a 250 mm Beckman ODS reverse phase column using a gradient mobile phase. The mass spectrometer was operated in positive ionization mode using TurboionSpray and precursor-product ion combinations of m/z 391.1-->305.1 and 371.1-->247.0 were monitored for oxaliplatin and carboplatin, the internal standard, respectively. The lower limit of quantitation for oxaliplatin was 20 ng/ml. The linear range of the method was 20-1000 ng/ml. The between- and within-day relative standard deviations ranged from 3.1 to 7.7%, and accuracy was within 5%. This method was successfully applied in a clinical study of oxaliplatin.

Publication types

  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / blood*
  • Antineoplastic Agents / pharmacokinetics
  • Chromatography, High Pressure Liquid / methods*
  • Humans
  • Organoplatinum Compounds / blood*
  • Organoplatinum Compounds / pharmacokinetics
  • Oxaliplatin
  • Plasma / chemistry*
  • Reproducibility of Results
  • Tandem Mass Spectrometry / methods*
  • Ultrafiltration

Substances

  • Antineoplastic Agents
  • Organoplatinum Compounds
  • Oxaliplatin